About Platform Pipeline Patients Investors & News Careers Patients’ needs propel us forward Our mission & values We are on a mission to harness the microbiome to transform the lives of patients. To achieve our mission, we have assembled a team of multi-disciplinary experts and built a culture that values collaboration and a diversity of perspectives and ideas. Our team is united by our collective desire to develop a novel class of therapeutics for patients and families battling serious conditions linked to disruption of the microbiome. Built into our company DNA is a strong commitment to living our core values and utilizing them to guide our decisions and actions. Patients first We have an unwavering commitment to putting the needs of patients first in everything we do Tenacity We work relentlessly to achieve our mission and deliver on our commitments Humility We maintain open minds and constantly work to expand our knowledge Daring We push scientific boundaries and ourselves Community We are committed to nurturing a strong, diverse community within Finch and giving back to the external communities we are a part of Our leadership team Our leadership team is comprised of seasoned biotech executives and recognized leaders in the microbiome field—clinicians and scientists that have paved the way for a new class of therapeutics with the potential to treat a wide range of conditions linked to disruption of the microbiome. Our leadership team combines decades of experience in the areas of microbiology, data science, clinical research, and the manufacture and commercialization of complex biologics. Mark Smith, PhD Chief Executive Officer Greg Perry Chief Financial Officer Debra Silberg, MD, PhD Interim Chief Medical Officer Michelle Rose, PhD Chief Regulatory Officer Marc Blaustein Chief Operating Officer Jim Sigler, MBA Executive Vice President of CMC Sonia Timberlake, PhD Senior Vice President, Research Joseph Vittiglio, JD General Counsel James Burgess Vice President, Innovation Martina Schinke, PhD Vice President, Program Management Irina Koroleva, PhD Vice President, Translational Medicine David Rhodes, PhD Vice President, Technical Development Anne Marie Conway, MHA, RN Vice President, Clinical Operations Rozanna Yaing, MBA Vice President, Quality Mitch Jones, MD, PHD Vice President, Clinical Discovery and Development David Pugatch, MD Vice President, Clinical Development Steve Klincewicz, DO, MPH, JD Vice President, Drug Safety and Pharmacovigilance Matt Nelson, MBA Vice President, Finance Domenic Ferrante Susan E. Graf Nicholas Haft Al Hamood Christian Lange Chris Shumway Jeffery Smisek Mark Smith, PhD Jo Viney, PhD Key milestones in the field & Finch’s history 4th century First written accounts emerge from China of therapeutic applications of microbial therapies. 1958 Ben Eiseman et al. publishes first report of four patients with pseudomembranous enterocolitis treated with microbiota transplantation. 1983 Anna Schwan et al. publishes first report of C. difficile infection treated with microbiota transplantation. 1988 Thomas Borody, founder of the Centre for Digestive Diseases in Australia, begins treating patients with microbiota transplantation and subsequently publishes 59 case reports describing the use of this novel approach for a variety of different conditions, such as ulcerative colitis and Crohn’s disease. Borody goes on to carry out thousands of microbiota transplantations and his work will help catalyze microbiome research around the world. Contact us info@finchtherapeutics.com 617-229-6499 200 Inner Belt Road, Suite 400, Somerville, MA, 02143 Policies © 2021 Finch Therapeutics Group, Inc. All rights reserved.